DSK Legal advised HealthQuad Fund II (“HealthQuad”) in relation to its subscription of securities in the Series B funding round of Redcliffe Lifetech Private Limited and Redcliffe Lifetech Inc. (“Investee Companies”), as one of the major investors along with Vistra ITCL (India) Limited, Amicorp Trustees (India) Private Limited, and Shubharambh Investment Holdings (Leap Frog) (“Transaction”).
The Investee Companies are engaged in the business providing diagnostics services including pathology (including but not limited to routine biochemistry, immunoassay, histopathology, microbiology, etc.), radiology, advanced genomic tests and services, both via online and offline channels.
DSK Legal advised HealthQuad on drafting, negotiating, and finalising: (a) the transaction documents in relation to HealthQuad’s investment in the Indian Investee Company; and (b) the transaction documents for its investment in the US Investee Company.
The DSK Legal team representing HealthQuad Fund II on the Transaction comprised of Rishi Anand (Partner), Nakul Batra (Associate Partner) and Snigdha Prakash (Associate).
The Investee Companies, i.e., Redcliffe Lifetech Private Limited and Redcliffe Lifetech Inc., were represented by Vertices Law.
Shardul Amarchand Mangaldas & Co. represented Shubharambh Investment Holdings (Leap Frog).